Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 6Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 52Radiotherapy 43Cetuximab 30Fluorouracil 27pembrolizumab 19Carboplatin 19Docetaxel 14Paclitaxel 8Radiotherapy, Intensity-Modulated 7Nivolumab 6Methotrexate 6Drug Therapy 6Surgical Procedures, Operative 5Chemotherapy, Adjuvant 5Radiation 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4nimotuzumab 3Taxes 3Chemoradiotherapy 3toripalimab 2lenvatinib 2epacadostat 2durvalumab 2dehydroftorafur 2camrelizumab 2avelumab 2advexin 2Specimen Handling 2Radiotherapy, Conformal 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Squamous Cell Carcinoma of Head and Neck × epacadostat × Clear all
NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Incyte Corporation

Phase 3 Completed
89 enrolled 14 charts
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Incyte Corporation

Phase 3 Withdrawn
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡